CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer
- 22 January 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (11), 2595-2602
- https://doi.org/10.1158/1078-0432.ccr-19-1669
Abstract
Purpose: The potential biological determinants of aggressive prostate cancer (PCa) in African American (AA) men are unknown. Here we characterize PCa genomic alterations in the largest cohort to date of AA men with clinical follow-up for metastasis, with the aim to elucidate the key molecular drivers associated with poor prognosis in this population. Experimental Design: Targeted sequencing was retrospectively performed on 205 prostate tumors from AA men treated with radical prostatectomy (RP) to examine somatic genomic alterations and percent genome alteration (PGA). Cox proportional hazards analyses assessed the association of genomic alterations with risk of metastasis. Results: At RP, 71% (145/205) of patients had grade group ³3 disease, and 49% (99/202) were non-organ-confined. The median PGA was 3.7% (IQR 0.9-9.4%) and differed by pathologic grade (pSPOP (11.2%), FOXA1 (8.3%), and TP53 (3.9%). The most common loci altered at the copy number level were CDKN1B (6.3%), CHD1 (4.4%), and PTEN (3.4%). TP53 mutations and deep deletions in CDKN1B were associated with increased risks of metastasis on multivariable analyses (TP53: HR 9.5, 95% CI 2.2-40.6, p=0.002; CDKN1B: HR 6.7, 95% CI 1.3-35.2, p=0.026). Conclusions: Overall, PGA, somatic TP53 mutations, and a novel finding of deep deletions in CDKN1B were associated with poor prognosis in AA men. These findings require confirmation in additional AA cohorts.Other Versions
Funding Information
- Health Disparity Research
- CDMRP-PCRP (W81XWH-15-1-0661)
- NIH
- NCI (P50 CA58236, P50 CA186786-05, P50 CA180995)
- NCI (5P30CA006973-52)
- Prostate Cancer Foundation
- Polsky Urologic Cancer Institute
This publication has 48 references indexed in Scilit:
- Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosisOncology Letters, 2013
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerNature Genetics, 2012
- Using Molecular Markers to Help Predict Who Will Fail after Radical ProstatectomyProstate Cancer, 2011
- Impact of Socioeconomic Factors on Prostate Cancer Outcomes in Black Patients Treated with SurgeryUrology, 2008
- Prognostic Value of Abnormal p53 Expression in Locally Advanced Prostate Cancer Treated With Androgen Deprivation and Radiotherapy: A Study Based on RTOG 9202International Journal of Radiation Oncology*Biology*Physics, 2007
- A Polymorphism in the CDKN1B Gene Is Associated with Increased Risk of Hereditary Prostate CancerCancer Research, 2004
- A Genome Screen of Families with Multiple Cases of Prostate Cancer: Evidence of Genetic HeterogeneityAmerican Journal of Human Genetics, 2001
- LOSS OF HETEROZYGOSITY AT 12P12–13 IN PRIMARY AND METASTATIC PROSTATE ADENOCARCINOMAJournal of Urology, 2000
- A Genome Screen of Multiplex Sibships with Prostate CancerAmerican Journal of Human Genetics, 2000